Navigation Links
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/3/2008

mely manner; our need for capital, risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and our adjuvant in a timely manner; that enough HspE7 will be available to conduct our planned trials; that we will be able to procure the necessary amount of adjuvant to conduct our planned trials; that we will obtain timely approval from additional IRBs; that the results from additional preclinical and clinical work, if any, will be consistent with the results we have already obtained; that a sufficient number of patients will be available to conduct our planned trials; and that sufficient data will be generated to support our IND.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

F
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015  Research and Benchmarking firm, Best Practices, ... Affairs Roundtable on Thursday, May 28th from ... to discuss "Medical Affairs, Role in Health Economics ... Affairs Consortium provides Medical Affairs leaders with a ... they face. The consortium has developed a mechanism ...
(Date:5/22/2015)... 22 2015 /CNW/ - The Taskforce representing Canada,s ... all the hard work that the Minister and Health Canada ... This program recognizes the needs of the thalidomide survivors, and ... a year, tax free, with annual adjustments for inflation. ... annual payments of $100,000 based on the severity of their ...
(Date:5/22/2015)... May 22, 2015  Amgen (NASDAQ: ... commenced termination of its participation in the ... (LON:AZN, STO:AZN and NYSE: AZN ).  ... development for patients with moderate-to-severe plaque psoriasis, ... was based on events of suicidal ideation ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... , OKLAHOMA CITY , July 12 For the ... to receive its prestigious R&D 100 Award.  Orthocare Innovations received this ... reporting the function of persons who have experienced lower limb loss, injury ... (Logo:   ...
... 12 Holon, the new standard for healthcare interoperability, ... , , ... the Holon Process Adaptive Interoperability Framework, Holon introduces a cost-effective ... solution by automating the collection and distribution of pharmacy information ...
Cached Medicine Technology:Orthocare Innovations Receives Prestigious R&D 100 Award for Novel Web-Based Rehabilitation Outcomes Assessment System 2Holon: The Process Adaptive Interoperability Framework 2
(Date:5/25/2015)... 25, 2015 According to a recently ... growth in hip external fixation market is driven by ... population and advancements in infection prevention technologies. As the ... are currently accounting for the largest total number of ... falls and accidents. As a result, the average selling ...
(Date:5/25/2015)... Boston, MA (PRWEB) May 25, 2015 A ... 28th, 2015 states 1,000 persons have died as a direct ... in 2014. This marks a 33% rise in overdose deaths ... Gov. Charlie Baker, “This issue doesn’t care about geography. This ... income. This issue doesn’t care about class.” As the state ...
(Date:5/25/2015)... Stanley Consultants has been awarded ... the wastewater treatment expansion at the South ... Recognition Award from the American Council of Engineering Companies ... Competitions held by the organization honor the year’s ... is Iowa City’s largest public works project ever. ...
(Date:5/25/2015)... 2015 Thousands of DePuy Pinnacle ... in the federal multidistrict litigation now underway in ... to a Motion filed on May 20th, plaintiffs’ ... Case Management Order pertaining to the Limited Authorization ... Motion seeks the adoption of a new form ...
(Date:5/25/2015)... May 25, 2015 ProDrop Light Show ... VJ neon light backdrops with a click of a mouse. Users ... much more all within Final Cut Pro X. , ProDrop Light ... as drop zones, kaleidoscope and much more leaving infinite possibilities all ... drop zones and text presets, users can apply their very ...
Breaking Medicine News(10 mins):Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 3Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2
... the order in which two drugs are taken significantly extended ... has found., Women who took the drugs anastrozole and fulvestrant ... who took the drugs in sequence, researchers reported Dec. 7 ... most likely will change the standard of care for how ...
... to help her children better resist the temptations of drug ... University of Adelaide. A paper published in the ... in the United States and the University of Adelaide shows ... immune system in the brain. Using rats as a ...
... 7, 2011 HOBOKEN, NJ Keeping your brain ... supplementing a healthy diet is just as important to ... abs. Natural supplements are an easy, effective way to ... Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark ...
... By Serena Gordon HealthDay Reporter , TUESDAY, Dec. ... more than leave you tired; it may also increase your risk ... study of two groups of women found that those who worked ... than women with regular hours, and the longer that they worked ...
... University Hospitals Case Medical Center in Cleveland, Ohio is ... "Top Hospital" and leader in quality patient care by ... which is the most competitive national hospital quality award ... quality care by preventing medical errors, reducing mortality for ...
... Kathleen Doheny HealthDay Reporter , TUESDAY, Dec. ... lower their risk of dying from breast cancer by ... "Our study adds further to the evidence that mammography ... Otto, a senior researcher in the department of public ...
Cached Medicine News:Health News:Changing order drugs are taken boosts breast cancer survival 2Health News:A mother's touch may protect against drug cravings 2Health News:Pycnogenol® found to improve memory and test scores in college students in new clinical trial 2Health News:Rotating Shift Work May Boost Women's Diabetes Risk 2Health News:Rotating Shift Work May Boost Women's Diabetes Risk 3Health News:University Hospitals Case Medical Center recognized as national leader by the Leapfrog Group 2Health News:Mammograms Cut Risk of Breast Cancer Death by Half, Study Finds 2
... Another first for Linvatec! The EnVision ... experience and proprietary technology to ensure ... Linvatecs Shockflex prism system gives our ... protect their investment. With an integrated ...
... customized digital camera offers maximum ... video needs. With internal video ... to best meet your specific ... are interchangeable with autoclavable and ...
... 1-Chip Camera System provides easy-to-use features, auto ... scope. The camera head construction is based ... 14, Complete 1-Chip Camera System, International (GS ... Unit (CCU) with video cables , (GS ...
... 1-Chip Camera System provides easy-to-use features, auto ... scope. The camera head construction is based ... 12, Complete 1-Chip Camera System, International (GS9900-PAL) ... (CCU) with power cord and video cables ...
Medicine Products: